OKYO Pharma Limited (OKYO) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
55 Park Lane
London, W1K 1NA
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 20 7495 2379
Website
Sector
Healthcare
Industry
Biotechnology
Employees
3
First IPO Date
May 17, 2022
| Name | Title | Pay | Year Born |
| Robert J. Dempsey | Chief Executive Officer & Executive Director | 450,000 | N/A |
| Gary S. Jacob | Chief Development Officer & Director | 450,000 | 1947 |
| Rajkumar Patil | Chief Scientific Officer | 0 | 1959 |
| Michael Paul Beck | Founder | 0 | 1957 |
| Keeren Shah | Chief Financial Officer | 0 | 1976 |
| Flavio Mantelli | Chief Medical Officer | 0 | N/A |
OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain. Established in 2007, OKYO Pharma Limited maintains its headquarters in London, UK.